Syngeneic Models

Syngeneic Mouse Models for Oncology Research

Syngeneic mouse models (also known as allograft mouse tumor systems) differ from humanized ones by the origin of the cancer being monitored. In humanized models, cancer cells are taken directly from a human, while in syngeneic ones, the cancer cells are derived from mice or genetically similar rodents.

As a result of the murine origin of cancers used in syngeneic models, the immune system of a mouse does not have to be impaired; the cells will be accepted by the host mouse. This allows for an environment nuanced with an immune system, helping researchers determine the side effects of a given anti-cancer drug in the context of a full immune response. However, the immune system of mice differs from that of humans, and hence the results of a drug may differ in each organism. This barrier to a realistic setting for tumor monitoring has been the subject of many developments over the past few decades, resulting in extensive efforts to make humanized mice with functioning human immune systems.

Syngeneic mouse models were used by early cancer researchers to determine the general efficiency of novel chemotherapies. Tumor growth was monitored in the presence of different chemicals, giving clues as to how various treatments were affecting generic tumor growth. Nowadays the models have become less relevant as the differences between mice and humans significantly affects the effectiveness of drugs.

Altogen Labs Syngeneic Mouse Models:

  • 4T1 (Breast Cancer)
  • CT26, MC38 (Colon Cancer)
  • P338 (Leukemia)
  • KLN 205 (Lung Cancer)
  • A20, EL4 (Lymphoma)
  • P815 (Mastocytoma)
  • B16-F10 (Melanoma)
  • Renca (Kidney Cancer)